Adeno-associated virus-mediated neural repair in parkinson's disease: a systematic review from animal models to clinical trials
Abstract
In response to the limitations of existing treatment methods, the development of new treatment approaches that can delay or reverse the neurodegenerative process has become a research hotspot. Gene therapy, especially strategies based on adeno-associated virus (AAV) vectors, is emerging as a research frontier in the treatment of Parkinson's disease due to its high efficiency, low immunogenicity, long-term stable expression, and neuron tropism in the nervous system. Recent clinical trials have demonstrated significant improvements in motor function, with some approaches showing up to 36% enhancement in UPDRS scores. AAV-mediated gene therapy mainly focuses on the following therapeutic targets: dopamine pathway reconstruction, neurotrophic factor delivery, -synuclein clearance strategies, and emerging therapeutic targets. The main purpose of this review is to evaluate the latest research progress of AAV vector gene therapy in Parkinson's disease, focusing on analyzing its potential and challenges in the preclinical and clinical translation process and proposing possible optimization paths to promote the clinical application of gene therapy.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.